Effect of Corona Virus on Intravitreal Injections

Diabetic Retinopathy Clinical Trial

Official title:

Effects of Corona Virus Pandemic on Intravitreal Injections

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05494775
• Other study ID #: Rc-11-2022
• Status: Recruiting
• Phase: N/A
• Start date: February 1, 2019
• Est. completion date: July 30, 2023

Study information

• Verified date: August 2022
• Source: Benha University
• Contact: Ahmed A Tabl, MD
• Phone: 01222328766
• Email: ahmad4lg[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

During pandemic of corona virus, patients compliance may be affected. We aim to study the factors lead to unregulated visits and its implications on the final visual outcome.

Description:

The corona virus pandemic may affects patients regular visits to ophthalmic clinic, we aim to study the sequel of the pandemic on intravitreal injections results in diabetic macular edema, wet age related macular degenerations, myopic choroidal new vascularization, and proliferative diabetic retinopathy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 250
• Est. completion date: July 30, 2023
• Est. primary completion date: June 11, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 80 Years

Eligibility

Inclusion Criteria:

• patients with the following conditions (diabetic macular edema, wet age related macular degeneration, myopic choroidal new vascularization and retinal vein occlusion complicated with macular edema).

Exclusion Criteria:

• patients that are known to have hypersensitivity to Anti-VEGFs.

Related Conditions & MeSH terms

• Age-Related Macular Degeneration
• Choroidal Neovascularization
• Coronavirus Infections
• Diabetic Macular Edema
• Diabetic Retinopathy
• Macular Degeneration
• Macular Edema
• Myopic Choroidal Neovascularisation
• Neovascularization, Pathologic

Intervention

Drug:
• Anti-vascular endothelial growth factors (Anti-VEGFs)
Intravitreal injection of anti-vascular endothelial growth factors (Anti-VEGFs).

Locations

Country	Name	City	State
Egypt	Ahmed Abdelshafy Tabl	Banha	Benha

Sponsors (1)

Lead Sponsor	Collaborator
Benha University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Visual acuity	Assessing the changes in best corrected visual acuity in logMAR unit measured by snellen chart.	Baseline and monthly after injection till one year of follow-up
Secondary	Central subfield thickness	Assessing the changes in central macular thickness in microns measured by optical coherence tomography	Baseline and monthly after injection till one year of follow-up